Compare ARDX & SLRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARDX | SLRC |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 797.8M | 691.2M |
| IPO Year | 2014 | 2007 |
| Metric | ARDX | SLRC |
|---|---|---|
| Price | $3.02 | $11.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | $12.80 | ★ $14.69 |
| AVG Volume (30 Days) | ★ 4.3M | 364.4K |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 10.50% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | ★ $2,607,000.00 | N/A |
| Revenue This Year | $19.21 | N/A |
| Revenue Next Year | $28.19 | $1.70 |
| P/E Ratio | ★ N/A | $25.09 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.96 | $10.96 |
| 52 Week High | $8.40 | $16.36 |
| Indicator | ARDX | SLRC |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 53.51 |
| Support Level | N/A | $11.23 |
| Resistance Level | $3.35 | $13.33 |
| Average True Range (ATR) | 0.12 | 0.23 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 25.32 | 78.72 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. The company's investment objective is to generate both current income and capital appreciation through debt and equity investments. The company invests principally in leveraged middle-market companies in the form of senior secured loans, financing leases, and to a lesser extent, unsecured loans and equity securities.